Phio Pharmaceuticals
NASDAQ: PHIOMarlborough, US · Delaware corporation
Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing INTASYL, a proprietary self-delivering siRNA gene silencing technology that makes immune cells more effective at killing cancer cells. Its immuno-oncology pipeline targets cutaneous squamous cell carcinoma (cSCC) and melanoma.
Founders & leadership
CM
Craig MelloCo-founder
GC
Geert CauwenberghinExecutive
GD
Gerrit DispersyninExecutive
CL
Curtis LockshinNamed on SEC filing
PD
Paul DormanNamed on SEC filing
KB
Keith BrownlieNamed on SEC filing
Board
CL
Curtis Lockshin, Ph.D.Board director
RJ
Robert J. BittermanBoard director
JE
Jonathan E. FreemanBoard director
PA
Patricia A. BradfordBoard director
RL
Robert L. FerraraBoard director
Reported raises · per SEC filings
Form D private placements$32.3M disclosed across 16 rounds · 2017–2025
▶$1.4MraisedNov 2025 · 5 investors · BiotechnologyRule 506(b)
▶$1.4MraisedNov 2025 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Curtis Lockshin, Ph.D.Director
- Patricia A. BradfordDirector
- Robert J. BittermanDirector, Executive Officer
- Lisa CarsonExecutive Officer
- David H. DemingDirector
- Jonathan FreemanDirector
- Offering amount
- $25.9M
- Amount sold
- $1.4M
- Sales commissions
- $1.1M
- Placement agents
- H.C. Wainwright & Co, LLC
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$232.1KraisedAug 2025 · 2 investors · BiotechnologyRule 506(b)
▶$232.1KraisedAug 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert FerraraDirector
- Jonathan FreemanDirector
- Lisa CarsonExecutive Officer
- Robert J. BittermanDirector, Executive Officer
- David H. DemingDirector
- Curtis Lockshin, Ph.D.Director
- Patricia A. BradfordDirector
- Offering amount
- $5.1M
- Amount sold
- $232.1K
- Sales commissions
- $261.8K
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$152.5KraisedJan 2025 · 4 investors · BiotechnologyRule 506(b)
▶$152.5KraisedJan 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Curtis Lockshin, Ph.D.Director
- Patricia A. BradfordDirector
- Robert FerraraDirector
- Robert InfarinatoExecutive Officer, Promoter
- Robert J. BittermanDirector, Executive Officer
- Jonathan FreemanDirector
- Offering amount
- $3.7M
- Amount sold
- $152.5K
- Sales commissions
- $185.6K
- Placement agents
- H.C. Wainwright & Co, LLC
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$265.9KraisedJan 2025 · 4 investors · BiotechnologyRule 506(b)
▶$265.9KraisedJan 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert J. BittermanDirector, Executive Officer
- Robert InfarinatoExecutive Officer
- Jonathan FreemanDirector
- Patricia A. BradfordDirector
- Robert FerraraDirector
- Curtis Lockshin, Ph.D.Director
- Offering amount
- $6.4M
- Amount sold
- $265.9K
- Sales commissions
- $312.2K
- Placement agents
- H.C. Wainwright & Co, LLC
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$208.3KraisedJan 2025 · 4 investors · BiotechnologyRule 506(b)
▶$208.3KraisedJan 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert FerraraDirector
- Robert InfarinatoExecutive Officer, Promoter
- Robert J. BittermanDirector, Executive Officer
- Jonathan FreemanDirector
- Patricia A. BradfordDirector
- Curtis Lockshin, Ph.D.Director
- Offering amount
- $5M
- Amount sold
- $208.3K
- Sales commissions
- $253.4K
- Placement agents
- H.C. Wainwright & Co, LLC
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30KraisedJan 2025 · 4 investors · BiotechnologyRule 506(b)
▶$30KraisedJan 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patricia A. BradfordDirector
- Curtis Lockshin, Ph.D.Director
- Robert InfarinatoExecutive Officer
- Jonathan FreemanDirector
- Robert FerraraDirector
- Robert J. BittermanDirector, Executive Officer
- Offering amount
- $480K
- Amount sold
- $30K
- Sales commissions
- $60.8K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$54.6KraisedJan 2025 · 4 investors · BiotechnologyRule 506(b)
▶$54.6KraisedJan 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patricia A. BradfordDirector
- Robert J. BittermanDirector, Executive Officer
- Robert InfarinatoExecutive Officer
- Robert FerraraDirector
- Curtis Lockshin, Ph.D.Director
- Jonathan FreemanDirector
- Offering amount
- $1.3M
- Amount sold
- $54.6K
- Sales commissions
- $138.9K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$136.3KraisedJul 2024 · 8 investors · BiotechnologyRule 506(b)
▶$136.3KraisedJul 2024 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Curtis A. Lockshin, Ph.D.Director
- Robert J. BittermanDirector, Executive Officer
- Jonathan E. FreemanDirector
- Patricia A. BradfordDirector
- Robert L. FerraraDirector
- Offering amount
- $6.4M
- Amount sold
- $136.3K
- Sales commissions
- $349.2K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
StockTwits19 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
TradingView16 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Robinhood15 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha14 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Phio Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Phio Pharmaceuticals do?
- Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing INTASYL, a proprietary self-delivering siRNA gene silencing technology that makes immune cells more effective at killing cancer cells. Its immuno-oncology pipeline targets cutaneous squamous cell carcinoma (cSCC) and melanoma.
- Who founded Phio Pharmaceuticals?
- Phio Pharmaceuticals was founded by Craig Mello.
- How much funding has Phio Pharmaceuticals raised?
- Phio Pharmaceuticals has disclosed $32.3M raised across 16 rounds.
- Where is Phio Pharmaceuticals headquartered?
- Phio Pharmaceuticals is headquartered in Marlborough, US.